KRAS and adenocarcinoma: 7.7% of KRAS-associated lung cancers were adenocarcinomas (Table 2) and 6.1% of KRAS mutations associated with ‘low differentiation’ cancers and 7.4% of KRAS mutations were ‘mid differentiation’ cancers (Table 3).